Cited by 122Glutathione Transferases and PolymorphismsPharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity

Simon, T·2000·Clinical Pharmacology & Therapeutics

DOI 10.1067/mcp.2000.104944

Open this paper in CoChat — free account

Abstract

BACKGROUND: Glutathione conjugation of tacrine reactive metabolites depends in part on the activity of glutathione-S-transferases (GST), of which two isozymes (GST M1 and GST T1) are polymorphically expressed. OBJECTIVE AND METHODS: To determine whether GST M1, GST T1, and the combined GST M1 and GST T1 null genotypes predict individual susceptibility to tacrine hepatotoxicity, 141 patients with mild to moderate Alzheimer's disease treated with tacrine were genotyped. RESULTS: During the treatment period, 52 patients had elevated alanine aminotransferase (ALT) levels at least three times the upper limit of normal, whereas 89 patients had normal ALT values (< or = upper limit of normal). Both groups were comparable in demographic and clinical characteristics. Twenty-eight patients were found to be GST T1-negative (20%; with a 95% confidence interval [95% CI] from 13% to 27%), and 68 patients (48%; 95% CI from 40% to 57%) were GST M1-negative. The combined GST M1-T1 null genotype was observed in 18 patients (13%; 95% CI from 7% to 18%) of whom 13 had an elevated plasma ALT at least three times the upper limit of normal during the study period. Although the cumulative percentage of elevated plasma ALT tended to be higher in the GST M1 null genotype, neither GST M1 nor GST T1 alone could predict individual susceptibility to tacrine hepatotoxicity. Multivariate Cox hazards model showed that the association of the GST M1-T1 null genotype was an independent risk factor of hepatotoxicity. CONCLUSIONS: The presence of combined alleles M1 and T1 deficiencies in glutathione-S-transferase genes increases the susceptibility to tacrine hepatotoxicity.

Integrity signals

Registry

Crossref · 10.1067/mcp.2000.104944

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism
Pemble, S. E., Schroeder, K., Spencer, S. R., Meyer, D. J., Hallier, E., Bolt, H. M., KETTERER, B., & Taylor, J. B. (1994) · Biochemical Journal · doi:10.1042/bj3000271 · Cited by 1,296
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. R. (1992) · JAMA · doi:10.1001/jama.268.18.2523 · Cited by 632
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Association Between Glutathione S-Transferase M1, P1, and T1 Genetic Polymorphisms and Development of Breast Cancer
Helzlsouer, K. J., Huang, H., Hoffman, S. C., Alberg, A. J., Comstock, G. W., Strickland, P. T., Selmin, O. I., Watson, M., & Bell, D. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.7.512 · Cited by 292
Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans.
Bailey, L., Roodi, N., Verrier, C. S., Yee, C. J., Dupont, W. D., & Parl, F. F. (1998) · PubMed · Cited by 212
An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro
Madden, S. F., Woolf, T. F., Pool, W. F., & Park, B. K. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90342-t · Cited by 103
Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class Mu gene detected by polymerase chain reaction
Brockmöller, J., Gross, D., Kerb, R., Drakoulis, N., & Roots, I. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90591-6 · Cited by 99

Flagged first, then by citations

Show all 25 references

1 of the 25 references couldn’t be matched to a known paper.

Sorted by citations

Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Drug-Induced Liver Injury
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 480
Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Russmann, S., Kullak-Ublick, G. A., & Grattagliano, I. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803097 · Cited by 412
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D. A., Zineh, I., Giacomini, K. M., & Krauss, R. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2423 · Cited by 400
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity
Walgren, J. L., Mitchell, M. D., & Thompson, D. C. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935620 · Cited by 320
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 275
Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
Paz, M. V., Morán, L., López‐Alcántara, N., Freixo, C., Andrade, R. J., Lucena, M. I., & Cubero, F. J. (2021) · Antioxidants · doi:10.3390/antiox10030390 · Cited by 234
Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury
Huang, Y., Su, W., Huang, Y., Chen, C., Chang, F.-Y., Lin, H., & Lee, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.009 · Cited by 212
Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury†
Lucena, M. I., Andrade, R. J., Martínez, C., Ulzurrun, E., García‐Martín, E., Borraz, Y., Fernández, M. C., Romero‐Gómez, M., Castiella, A., Planas, R., et al. (2008) · Hepatology · doi:10.1002/hep.22370 · Cited by 194
Diagnosis, management and prevention of drug-induced liver injury
Verma, S., & Kaplowitz, N. (2009) · Gut · doi:10.1136/gut.2008.163675 · Cited by 194
A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus
Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00014-6 · Cited by 174
Drug‐Induced Liver Injury: The Role of Drug Metabolism and Transport
Corsini, A., & Bortolini, M. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.23 · Cited by 178
Pharmacogenetics of drug‐induced liver injury†
Russmann, S., Jetter, A., & Kullak-Ublick, G. A. (2010) · Hepatology · doi:10.1002/hep.23720 · Cited by 145
Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods
Mihajlovic, M., & Vinken, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063315 · Cited by 132
Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma
Imanishi, H., Okamura, N., Yagi, M., Noro, Y., Moriya, Y., Nakamura, T., Hayakawa, A., Takeshima, Y., Sakaeda, T., Matsuo, M., et al. (2006) · Journal of Human Genetics · doi:10.1007/s10038-006-0096-z · Cited by 114
Pharmacogenomics of Anti-TB Drugs-Related Hepatotoxicity
Roy, P. D., Majumder, M., & Roy, B. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.3.311 · Cited by 114
Genetic Basis of Drug-Induced Liver Injury: Present and Future
Urban, T. J., Aithal, G. P., & Daly, A. K. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1375954 · Cited by 109
Copy number variants in pharmacogenetic genes
He, Y., Hoskins, J. M., & McLeod, H. L. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.007 · Cited by 110
EXPRESSION OF HUMAN PHASE II ENZYMES IN CHIMERIC MICE WITH HUMANIZED LIVER
Katoh, M., Matsui, T., Okumura, H., Nakajima, M., Nishimura, M., Naito, S., Tateno, C., Yoshizato, K., & Yokoi, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005157 · Cited by 102
Polymorphisms in glutathione S -transferase omega-1 and AD, vascular dementia, and stroke
Kölsch, H., Linnebank, M., Lütjohann, D., Jessen, F., Wüllner, U., Harbrecht, U., Thelen, K., Kreis, M., Hentschel, F., Schulz, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147294.29309.47 · Cited by 100
Pharmacogenomics of Adverse Drug Reactions: Practical Applications and Perspectives
Becquemont, L. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.37 · Cited by 96
Drug-Induced Liver Injury: Insights from Genetic Studies
Andrade, R. J., Robles‐Díaz, M., Ulzurrun, E., & Lucena, M. I. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.111 · Cited by 94
An algorithm for thorough background subtraction from high‐resolution LC/MS data: application for detection of glutathione‐trapped reactive metabolites
Zhang, H., & Yang, Y. (2008) · Journal of Mass Spectrometry · doi:10.1002/jms.1390 · Cited by 88
Chimeric mice with humanized liver
Katoh, M., Tateno, C., Yoshizato, K., & Yokoi, T. (2007) · Toxicology · doi:10.1016/j.tox.2007.11.012 · Cited by 87
Assessment of drug‐induced liver injury in clinical practice
Lucena, M. I., García‐Cortés, M., Cueto-Galán, R., Lopez‐Duran, J., & Andrade, R. J. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00566.x · Cited by 78
Role of pharmacogenomics in the treatment of tuberculosis: a review
Swaminathan, S., & Ramachandran, G. (2012) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s15454 · Cited by 75
Role of Human GlutathioneS-Transferases in the Inactivation of Reactive Metabolites of Clozapine
Dragović, S., Boerma, J. S., van Bergen, L., Vermeulen, N. P. E., & Commandeur, J. N. M. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100131f · Cited by 68
Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury
Huang, Y. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.1.1 · Cited by 68
Pharmacogenetics of Adverse Drug Reactions
Osanlou, O., Pirmohamed, M., & Daly, A. K. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.03.002 · Cited by 69
GlutathioneS-Transferase M1 Null Genotype as a Risk Factor for Carbamazepine-Induced Mild Hepatotoxicity
Ueda, K., Ishitsu, T., Seo, T., Ueda, N., Murata, T., Hori, M., & Nakagawa, K. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.5.435 · Cited by 66
Significance of genetic polymorphisms in glutathione S-transferase multigene family and lung cancer risk.
Reszka, E., & Wąsowicz, W. (2001) · PubMed · Cited by 61
GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis
Li, C., Long, J., Hu, X., & Zhou, Y. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1831-y · Cited by 54
Troglitazone
Yokoi, T. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_14 · Cited by 55
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease
Cacabelos, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1779700 · Cited by 51
Tacrine-induced liver damage: an analysis of 19 candidate genes
Alfirevic, A., Mills, T., Carr, D. F., Barratt, B. J., Jawaid, A., Sherwood, J. L., Smith, J. C., Tugwood, J. D., Hartkoorn, R. C., Owen, A., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f1f12b · Cited by 43
Analytical and Omics-Based Advances in the Study of Drug-Induced Liver Injury
Kralj, T., Brouwer, K. L. R., & Creek, D. J. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab069 · Cited by 43
Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?
Daly, A. K. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2091-1 · Cited by 41
Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy
Katz, D. A., Murray, B. P., Bhathena, A., & Sahelijo, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2486 · Cited by 41
Pharmacogenomics in neurology: Current state and future steps
Chan, A., Pirmohamed, M., & Comabella, M. (2011) · Annals of Neurology · doi:10.1002/ana.22502 · Cited by 37
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment
Verma, R., Patil, S., Zhang, N., Moreira, F. M. F., Vitorio, M. T., Santos, A. D. S., Wallace, E., Gnanashanmugam, D., Persing, D. H., Savić, R. M., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202103-0564oc · Cited by 36
Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
Lam, B., Hollingdrake, E., Kennedy, J. L., Black, S. E., & Masellis, M. (2009) · Human Genomics · doi:10.1186/1479-7364-4-2-91 · Cited by 36
Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implicationsPreprint
Ewart, L. C., Apostolou, A. P., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K., Joshipura, S. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472674 · Cited by 36
TNF,LTA,HSPA1LandHLA-DRGene Polymorphisms in HIV-Positive Patients with Hypersensitivity to Cotrimoxazole
Alfirevic, A., Vilar, F. J., Alsbou, M., Jawaid, A., Thomson, W., Ollier, W., Bowman, C. E., Delrieu, O., Park, B. K., & Pirmohamed, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.6 · Cited by 34
Hepatic injury due to drugs, herbal compounds, chemicals and toxins
Lewis, J. H., & Kleiner, D. E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00013-1 · Cited by 34
Genetic risk factors in the development of idiosyncratic drug-induced liver injury
Stephens, C., Lucena, M. I., & Andrade, R. J. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1854726 · Cited by 32
Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population
Gupta, V. H., Singh, M. M., Amarapurkar, D. N., Sasi, P., Joshi, J. M., Baijal, R., R., P. K. H., Amarapurkar, A. D., Joshi, K., & Wangikar, P. P. (2013) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31302-x · Cited by 33
Genetic Predisposition to Drug-Induced Liver Injury
Stephens, C. M., & Andrade, R. J. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2019.08.003 · Cited by 32
Involvement of Different Human Glutathione Transferase Isoforms in the Glutathione Conjugation of Reactive Metabolites of Troglitazone
Okada, R., Maeda, K., Nishiyama, T., Aoyama, S., Tozuka, Z., Hiratsuka, A., Ikeda, T., Kusuhara, H., & Sugiyama, Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040469 · Cited by 31
Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity
Carr, D. F., Alfirevic, A., Tugwood, J. D., Barratt, B. J., Sherwood, J. L., Smith, J. M., Pirmohamed, M., & Park, B. K. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f00919 · Cited by 30
Association between combinations of glutathione‐S‐transferase M1, T1 and P1 genotypes and non‐alcoholic fatty liver disease
Hori, M., Oniki, K., Nakagawa, T., Takata, K., 修一, 三., Marubayashi, T., & Nakagawa, K. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01794.x · Cited by 29
The pharmacogenomics of Alzheimer's disease
Crentsil, V. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2003.07.003 · Cited by 29
Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Polymorphisms in Glutathione S -Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease
Capurso, C. A., Panza, F., Seripa, D., Frisardi, V., Imbimbo, B. P., Verdile, G., Vendemiale, G., Pilotto, A., & Solfrizzi, V. (2010) · Rejuvenation Research · doi:10.1089/rej.2010.1052 · Cited by 27
Different Reactive Metabolites of Nevirapine Require Distinct GlutathioneS-Transferase Isoforms for Bioinactivation
Dekker, S. J., Zhang, Y., Vos, J. C., Vermeulen, N. P. E., & Commandeur, J. N. M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00250 · Cited by 23
Drugs and Toxins
Kleiner, D. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00012-1 · Cited by 24
Idiosyncratic drug hepatotoxicity: a 2008 update
Andrade, R. J., López-Ortega, S., López‐Vega, M. C., Robles‐Díaz, M., Cueto, I., & Lucena, M. I. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.2.261 · Cited by 22
Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide
Audemard‐Verger, A., Silva, N. M., Verstuyft, C., Costedoat-Chalumeau, N., Hummel, A., Guern, V. L., Sacré, K., Meyer, O., Daugas, É., Goujard, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151696 · Cited by 22
Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles
Botton, M. R., Lu, X., Zhao, G., Repnikova, E. A., Seki, Y., Gaedigk, A., Schadt, E. E., Edelmann, L. J., & Scott, S. A. (2019) · Human Mutation · doi:10.1002/humu.23855 · Cited by 22
Adverse Drug Reactions and Pharmacogenomics: Recent Advances
Alfirevic, A., & Pirmohamed, M. (2007) · Personalized Medicine · doi:10.2217/17410541.5.1.11 · Cited by 22
Glutathione S -Transferase GSTT1 and GSTM1 Allozymes: Beyond Null Alleles
Agúndez, J. A. G., & Ladero, J. M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.3.359 · Cited by 18
Host-environment medicine
Rabinowitz, P. M., & Poljak, A. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.11101.x · Cited by 16
Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
Shao, Q.-H., Mao, X., Zhou, Z., Huai, C., & Li, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.735260 · Cited by 15
PharmGKB summary
Thorn, C. F., Ji, Y., Weinshilboum, R. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283527c02 · Cited by 15
Utilization ofglutathione S-transferase Mu 1- andTheta 1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity studies
Arakawa, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.780027 · Cited by 17
Liver Disease Caused by Drugs
Teoh, N., Chitturi, S., & Farrell, G. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00086-x · Cited by 14
GSTT1/GSTM1 Genotype and Anti-Tuberculosis Drug-Induced Hepatotoxicity in Peruvian Patients
Jaramillo‐Valverde, L., Levano, K. S., Tarazona, D. D., Vásquez-Domínguez, A., Toledo-Nauto, A., Capristano, S., Sánchez, C., Tarazona‐Santos, E., Ugarte‐Gil, C., & Guio, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911028 · Cited by 13
In Vitro Investigation of the Glutathione Transferase M1 and T1 Null Genotypes as Risk Factors for Troglitazone-Induced Liver Injury
Usui, T., Hashizume, T., Katsumata, T., Yokoi, T., & Komuro, S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038661 · Cited by 13
Evaluation of Hepatic Glutathione Transferase Mu 1 and Theta 1 Activities in Humans and Mice Using Genotype Information
Arakawa, S., Fujimoto, K., Kato, A., Endo, S., Fukahori, A., Shinagawa, A., Fischer, T., Mueller, J., & Takasaki, W. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042911 · Cited by 12
Genetic and Epigenetic Basis of Drug-Induced Liver Injury
Singh, S., Kumar, P., Kumar, J. P., Tomo, S., Yadav, D., Sharma, P., Rao, M., & Banerjee, M. (2023) · Seminars in Liver Disease · doi:10.1055/a-2097-0531 · Cited by 12
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Stephens, C., Lucena, M. I., & Andrade, R. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64089-8 · Cited by 11
Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond
Gu, R., Liang, A., Liao, G., To, I., Shehu, A. I., & Ma, X. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000457 · Cited by 11
Evaluation of the association between null genotypes of glutathione-S-transferases and Behcet’s disease
Uzunoğlu, S., Acar, H., Okudan, N., Gökbel, H., Mevlitoğlu, İ., & Sarι, F. (2005) · Archives of Dermatological Research · doi:10.1007/s00403-005-0617-1 · Cited by 11
Pharmacological Treatment of Alzheimer`s Disease: Is it Progressing Adequately?
Robles, A. (2009) · The Open Neurology Journal · doi:10.2174/1874205x00903010027 · Cited by 11
Glutathione S-transferase M1 and T1 polymorphisms and the risk of mild hepatotoxicity induced by carbamazepine in a tunisian population study
Chbili, C., Hassine, A., Fathallah, N., Nouira, M., Salma, N., Ammou, S. B., & Saguem, S. (2018) · BMC Neurology · doi:10.1186/s12883-018-1013-8 · Cited by 10
Drug‐induced Hepatotoxicity
Larrey, D. G., Bedoya, J. U., & Meunier, L. (2017) · doi:10.1002/9781119251316.ch27 · Cited by 10
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Boelsterli, U. A., & Kashimshetty, R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01015-0 · Cited by 9
Dapsone‐Associated Methemoglobinemia in a Patient With SlowNAT2*5B Haplotype and Impaired Cytochromeb5Reductase Activity
Abouraya, M., Sacco, J., Hayes, K., Thomas, S. S., Kitchens, C. S., & Trepanier, L. A. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010393343 · Cited by 9
Glutathione Transferases
Mannervik, B., & Morgenstern, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00032-2 · Cited by 9
Embryonic and Induced Pluripotent Stem Cells as a Model for Liver Disease
Yagi, H., Tafaleng, E. N., Nagaya, M., Hansel, M. C., Strom, S. C., Fox, I. J., & Soto–Gutiérrez, A. (2009) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v37.i4-5.40 · Cited by 8
Direct and Rapid Genotyping of Glutathione-S-transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 Method
Okada, R., Ishizu, Y., Endo, R., Lezhava, A., Ieiri, I., Kusuhara, H., Sugiyama, Y., & Hayashizaki, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034652 · Cited by 8
Tailored Drug Therapy for Mitigating Drug-Induced Liver Injury: Is this The Era of Genetic Screening?
Huang, Y. (2009) · Personalized Medicine · doi:10.2217/pme.09.69 · Cited by 7
Central nervous system stimulants, drugs that suppress appetite, and drugs used in Alzheimer's disease
Sequeira, R. P. (2002) · Side effects of drugs annual · doi:10.1016/s0378-6080(02)80008-3 · Cited by 7
The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity
LaRocca, D., Lehmann, D. F., Perl, A., Ozawa, T., & Holohan, P. D. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02743.x · Cited by 7
Clinical Considerations of Drug-Induced Hepatotoxicity
Jain, S., & Kaplowitz, N. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01014-9 · Cited by 6
Glutathione Transferases
Armstrong, R. N., Morgenstern, R., & Philip G. Board (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64296-4 · Cited by 6
Clinical Considerations of Drug-Induced Hepatotoxicity
Motamedi, N., Kaplowitz, N., & Dara, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95665-4 · Cited by 6
Pharmacogenomics and Personalized Medicine for Infectious Diseases
Ganguly, N. K., & Saha, G. K. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_27 · Cited by 5
Frequency of null genotypes of glutathione S‐transferase M1 and T1 in Japanese patients with drug‐induced liver injury
Maeda, K., Takikawa, H., Aiso, M., Tsuji, K., Kagawa, T., Watanabe, M., Sato, K., Sakisaka, S., Hiasa, Y., Takei, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13812 · Cited by 5
Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins
Kleiner, D. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00012-0 · Cited by 4
Central nervous system stimulants, drugs that suppress appetite, and drugs used in Alzheimer's disease
Sequeira, R. P. (2001) · Side effects of drugs annual · doi:10.1016/s0378-6080(01)80006-4 · Cited by 4
MiR-743a-3p-mediated hepatic GSTM1 elimination aggravates acetaminophen-induced acute liver injury by inhibiting Sp1 nuclear translocation and SIRT1 expression
Xu, T., Pan, Y., Jin, Y., Ding, Q., Cao, F., Guo, R., Zhu, Q., Si, C., Song, Q., & Li, S. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.09.045 · Cited by 3
The search for genetic factors of predisposition to the development of liver cirrhosis in the course of viral hepatitis B in patients from the Republic of Bashkortostan
Гусманова, Г. Т., Kalimullina, D. K., Бакиров, А. Б., & Khusainova, R. I. (2012) · Kazan medical journal · doi:10.17816/kmj2287 · Cited by 3
Neurodegenerative Disorders: The Role of Genetic Factors in Their Origin and the Efficiency of Treatment
Sukhanov, V. A., Ionov, I. D., & Piruzyan, L. A. (2005) · Human Physiology · doi:10.1007/s10747-005-0080-6 · Cited by 3
Clinical implications of neuropharmacogenetics
Corvol, J., Devos, D., Hulot, J., & Lacomblez, L. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.04.003 · Cited by 3
Drug Induced Liver Disease: Mechanisms and Diagnosis
Andrade, R. J., & Lucena, M. I. (2010) · doi:10.1002/9781444314403.ch47 · Cited by 3
Drug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced Fatalities
Li, A. P. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch3 · Cited by 3
Use and Reuse of Animal Behavioral, Molecular, and Biochemical Data in Alzheimer’s Disease Research: Focus on 3Rs and Saving People’s Tax Dollars
Islam, M. A., Kshirsagar, S., Reddy, A. P., Sehar, U., & Reddy, P. H. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240126 · Cited by 2

Authors: Simon, T.
Affiliations: Inserm (FR)
Corresponding author: Simon, T
ORCID: Simon, T
Venue: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Published: 2000-04
Volume: 67
Issue: 4
Pages: 432-437
ISSN: 0009-9236 (ISSN-L)
DOI: 10.1067/mcp.2000.104944
OpenAlex: W2015114639
Cited by: 122
References: 25
Citations by year: 2025: 4 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 1 · 2013: 6 · 2012: 4
FWCI: 0.72
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords: tacrine, hepatotoxicity, glutathione S-transferase M1, glutathione S-transferase T1, genetic polymorphism, Alzheimer's disease, drug-induced liver injury, glutathione conjugation, alanine aminotransferase, pharmacogenetics, drug sensitivity
MeSH terms: Aged, Alleles, Alzheimer Disease, Female, Genotype, Glutathione Transferase, Humans, Isoenzymes, Liver, Liver Function Tests, Male, Parasympathomimetics, Pharmacogenetics, Polymorphism, Genetic, Tacrine, Proportional Hazards Models, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks